JP5032851B2 - キナゾリン誘導体 - Google Patents
キナゾリン誘導体 Download PDFInfo
- Publication number
- JP5032851B2 JP5032851B2 JP2006551898A JP2006551898A JP5032851B2 JP 5032851 B2 JP5032851 B2 JP 5032851B2 JP 2006551898 A JP2006551898 A JP 2006551898A JP 2006551898 A JP2006551898 A JP 2006551898A JP 5032851 B2 JP5032851 B2 JP 5032851B2
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- formula
- amino
- group
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 CC(C)(CC1*)CN(*)C1=O Chemical compound CC(C)(CC1*)CN(*)C1=O 0.000 description 6
- IWCYLFBJUBISCC-UHFFFAOYSA-N CN(Cc1cc2c(Nc(cccc3Cl)c3F)ncnc2cc1OC)C1(CCNCC1)C(N)=O Chemical compound CN(Cc1cc2c(Nc(cccc3Cl)c3F)ncnc2cc1OC)C1(CCNCC1)C(N)=O IWCYLFBJUBISCC-UHFFFAOYSA-N 0.000 description 2
- GCYWMKNZVNTVIY-UHFFFAOYSA-N CC(C(O)=O)N(Cc(cc1c(Nc(cccc2Cl)c2F)ncnc1c1)c1OC)C(COC)=C Chemical compound CC(C(O)=O)N(Cc(cc1c(Nc(cccc2Cl)c2F)ncnc1c1)c1OC)C(COC)=C GCYWMKNZVNTVIY-UHFFFAOYSA-N 0.000 description 1
- OJGQFAGYVWAAAD-ZDUSSCGKSA-N CC(C)N(Cc(cc1c(Nc(cccc2Cl)c2F)ncnc1c1)c1OC)[C@@H](C)C(N)=O Chemical compound CC(C)N(Cc(cc1c(Nc(cccc2Cl)c2F)ncnc1c1)c1OC)[C@@H](C)C(N)=O OJGQFAGYVWAAAD-ZDUSSCGKSA-N 0.000 description 1
- KPIGRPZFMNNBCP-UHFFFAOYSA-N CC(C)N(Cc(cc1c(Nc2cccc(Cl)c2F)ncnc1c1)c1OC)C(C)C(O)=O Chemical compound CC(C)N(Cc(cc1c(Nc2cccc(Cl)c2F)ncnc1c1)c1OC)C(C)C(O)=O KPIGRPZFMNNBCP-UHFFFAOYSA-N 0.000 description 1
- KPIGRPZFMNNBCP-CYBMUJFWSA-N CC(C)N(Cc1cc2c(Nc(cccc3Cl)c3F)ncnc2cc1OC)[C@H](C)C(O)=O Chemical compound CC(C)N(Cc1cc2c(Nc(cccc3Cl)c3F)ncnc2cc1OC)[C@H](C)C(O)=O KPIGRPZFMNNBCP-CYBMUJFWSA-N 0.000 description 1
- BVJNVOIYPXSNAN-UHFFFAOYSA-N CC(C)OCC(C(N)=O)NC(OCc1ccccc1)=O Chemical compound CC(C)OCC(C(N)=O)NC(OCc1ccccc1)=O BVJNVOIYPXSNAN-UHFFFAOYSA-N 0.000 description 1
- JPPAYRZURRWOMP-UHFFFAOYSA-N CC(C)OCC(C(OC)=O)NC(OCc1ccccc1)=O Chemical compound CC(C)OCC(C(OC)=O)NC(OCc1ccccc1)=O JPPAYRZURRWOMP-UHFFFAOYSA-N 0.000 description 1
- DYMBBDNTXACAEM-LBPRGKRZSA-N CC(C)OC[C@@H](C(O)=O)NC(OCc1ccccc1)=O Chemical compound CC(C)OC[C@@H](C(O)=O)NC(OCc1ccccc1)=O DYMBBDNTXACAEM-LBPRGKRZSA-N 0.000 description 1
- GFTHPCDXSGCQCO-UHFFFAOYSA-N CCN(Cc1cc2c(Nc(cccc3Cl)c3F)ncnc2cc1OC)C(C1)(CN1C(C)CC(N(C)C)=O)C(N)=O Chemical compound CCN(Cc1cc2c(Nc(cccc3Cl)c3F)ncnc2cc1OC)C(C1)(CN1C(C)CC(N(C)C)=O)C(N)=O GFTHPCDXSGCQCO-UHFFFAOYSA-N 0.000 description 1
- RFIFBBFZNIUSCT-UHFFFAOYSA-N CCOc1cc2ncnc(Nc(cccc3Cl)c3F)c2cc1CNC1(CCOCC1)C(O)=O Chemical compound CCOc1cc2ncnc(Nc(cccc3Cl)c3F)c2cc1CNC1(CCOCC1)C(O)=O RFIFBBFZNIUSCT-UHFFFAOYSA-N 0.000 description 1
- OIZPUCAXYYFFJE-UHFFFAOYSA-N CN(Cc1cc2c(Nc(cccc3Cl)c3F)ncnc2cc1OC)C1(CCN(CC2CC2)CC1)C(N)=O Chemical compound CN(Cc1cc2c(Nc(cccc3Cl)c3F)ncnc2cc1OC)C1(CCN(CC2CC2)CC1)C(N)=O OIZPUCAXYYFFJE-UHFFFAOYSA-N 0.000 description 1
- XMWCOOPLQWDGJN-UHFFFAOYSA-N CN(Cc1cc2c(Nc(cccc3Cl)c3F)ncnc2cc1OC)C1(CCOCC1)C(O)=O Chemical compound CN(Cc1cc2c(Nc(cccc3Cl)c3F)ncnc2cc1OC)C1(CCOCC1)C(O)=O XMWCOOPLQWDGJN-UHFFFAOYSA-N 0.000 description 1
- JLFUYZIWZMFTMH-UHFFFAOYSA-N CN(Cc1cc2c(Nc(cccc3Cl)c3F)ncnc2cc1OC)C1(CN(C)CCC1)C(N)=O Chemical compound CN(Cc1cc2c(Nc(cccc3Cl)c3F)ncnc2cc1OC)C1(CN(C)CCC1)C(N)=O JLFUYZIWZMFTMH-UHFFFAOYSA-N 0.000 description 1
- SGTONCVOTKXJAE-UHFFFAOYSA-N CN(Cc1cc2c(Nc(cccc3Cl)c3F)ncnc2cc1OC)C1(CN(C)CCC1)C(O)=O Chemical compound CN(Cc1cc2c(Nc(cccc3Cl)c3F)ncnc2cc1OC)C1(CN(C)CCC1)C(O)=O SGTONCVOTKXJAE-UHFFFAOYSA-N 0.000 description 1
- LJNUYDJKKBIGJB-QGZVFWFLSA-N CN(Cc1cc2c(Nc(cccc3Cl)c3F)ncnc2cc1OC)[C@H](COC)C(N)=O Chemical compound CN(Cc1cc2c(Nc(cccc3Cl)c3F)ncnc2cc1OC)[C@H](COC)C(N)=O LJNUYDJKKBIGJB-QGZVFWFLSA-N 0.000 description 1
- HXRACVFQPLBCAP-UHFFFAOYSA-N CNC(C1(CCOCC1)N(C)Cc1cc2c(Nc3cccc(Cl)c3F)ncnc2cc1OC)=O Chemical compound CNC(C1(CCOCC1)N(C)Cc1cc2c(Nc3cccc(Cl)c3F)ncnc2cc1OC)=O HXRACVFQPLBCAP-UHFFFAOYSA-N 0.000 description 1
- GTZJUBQWCWZING-UHFFFAOYSA-N COC(C(C1)N1C(OCc1ccccc1)=O)=O Chemical compound COC(C(C1)N1C(OCc1ccccc1)=O)=O GTZJUBQWCWZING-UHFFFAOYSA-N 0.000 description 1
- RLQRPFZBWXYXKT-UHFFFAOYSA-N COc1c(CN(CCC#N)CC(N)=O)cc2c(Nc(cccc3Cl)c3F)ncnc2c1 Chemical compound COc1c(CN(CCC#N)CC(N)=O)cc2c(Nc(cccc3Cl)c3F)ncnc2c1 RLQRPFZBWXYXKT-UHFFFAOYSA-N 0.000 description 1
- XWHXIIWBTYYFQA-UHFFFAOYSA-N COc1cc2ncnc(Nc(cccc3Cl)c3F)c2cc1C=O Chemical compound COc1cc2ncnc(Nc(cccc3Cl)c3F)c2cc1C=O XWHXIIWBTYYFQA-UHFFFAOYSA-N 0.000 description 1
- FUNDCHZZVLCUKX-UHFFFAOYSA-N COc1cc2ncnc(Nc(cccc3Cl)c3F)c2cc1CN(CCC#N)CC(O)=O Chemical compound COc1cc2ncnc(Nc(cccc3Cl)c3F)c2cc1CN(CCC#N)CC(O)=O FUNDCHZZVLCUKX-UHFFFAOYSA-N 0.000 description 1
- UKQXEKUEGLPLSV-UHFFFAOYSA-N COc1cc2ncnc(Nc(cccc3Cl)c3F)c2cc1CNC(CCCN1)C1=O Chemical compound COc1cc2ncnc(Nc(cccc3Cl)c3F)c2cc1CNC(CCCN1)C1=O UKQXEKUEGLPLSV-UHFFFAOYSA-N 0.000 description 1
- OFVLVHYPEYCUMY-UHFFFAOYSA-N COc1cc2ncnc(Nc3cccc(Cl)c3F)c2cc1CCCC(CCCN1)C1=O Chemical compound COc1cc2ncnc(Nc3cccc(Cl)c3F)c2cc1CCCC(CCCN1)C1=O OFVLVHYPEYCUMY-UHFFFAOYSA-N 0.000 description 1
- PTZCWFAROOJOMN-HNNXBMFYSA-N C[C@@H](C(N(CC1)CCC1(C(N)=O)N(C)Cc1cc2c(Nc(cccc3Cl)c3F)ncnc2cc1OC)=O)O Chemical compound C[C@@H](C(N(CC1)CCC1(C(N)=O)N(C)Cc1cc2c(Nc(cccc3Cl)c3F)ncnc2cc1OC)=O)O PTZCWFAROOJOMN-HNNXBMFYSA-N 0.000 description 1
- UEUGGJKCZZCQCG-KBPBESRZSA-N C[C@@H](COC)N(Cc(cc1c(Nc(cccc2Cl)c2F)ncnc1c1)c1OC)[C@@H](C)C(N)=O Chemical compound C[C@@H](COC)N(Cc(cc1c(Nc(cccc2Cl)c2F)ncnc1c1)c1OC)[C@@H](C)C(N)=O UEUGGJKCZZCQCG-KBPBESRZSA-N 0.000 description 1
- YCCMTCQQDULIFE-BYPYZUCNSA-N N[C@@H](CCCN1)C1=O Chemical compound N[C@@H](CCCN1)C1=O YCCMTCQQDULIFE-BYPYZUCNSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP04290274 | 2004-02-03 | ||
| EP04290274.2 | 2004-02-03 | ||
| PCT/GB2005/000237 WO2005075439A1 (en) | 2004-02-03 | 2005-01-31 | Quinazoline derivatives |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2007523072A JP2007523072A (ja) | 2007-08-16 |
| JP2007523072A5 JP2007523072A5 (cg-RX-API-DMAC7.html) | 2008-03-21 |
| JP5032851B2 true JP5032851B2 (ja) | 2012-09-26 |
Family
ID=34833782
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006551898A Expired - Fee Related JP5032851B2 (ja) | 2004-02-03 | 2005-01-31 | キナゾリン誘導体 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US7632840B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1713781B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP5032851B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN1914182B (cg-RX-API-DMAC7.html) |
| AR (1) | AR047703A1 (cg-RX-API-DMAC7.html) |
| AT (1) | ATE413389T1 (cg-RX-API-DMAC7.html) |
| DE (1) | DE602005010824D1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2315834T3 (cg-RX-API-DMAC7.html) |
| TW (1) | TW200529851A (cg-RX-API-DMAC7.html) |
| UY (1) | UY28736A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2005075439A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2004116911A (ru) * | 2001-11-03 | 2005-11-10 | Астразенека Аб (Se) | Производные хиназолина в качестве противоопухолевых средств |
| GB0126433D0 (en) * | 2001-11-03 | 2002-01-02 | Astrazeneca Ab | Compounds |
| GB0309009D0 (en) * | 2003-04-22 | 2003-05-28 | Astrazeneca Ab | Quinazoline derivatives |
| GB0309850D0 (en) * | 2003-04-30 | 2003-06-04 | Astrazeneca Ab | Quinazoline derivatives |
| GB0321648D0 (en) * | 2003-09-16 | 2003-10-15 | Astrazeneca Ab | Quinazoline derivatives |
| WO2005026156A1 (en) * | 2003-09-16 | 2005-03-24 | Astrazeneca Ab | Quinazoline derivatives |
| WO2005026150A1 (en) * | 2003-09-16 | 2005-03-24 | Astrazeneca Ab | Quinazoline derivatives as tyrosine kinase inhibitors |
| MXPA06002963A (es) * | 2003-09-16 | 2006-06-14 | Astrazeneca Ab | Derivados de quinazolina como inhibidores de cinasa de tirosina. |
| BRPI0414488A (pt) * | 2003-09-16 | 2006-11-14 | Astrazeneca Ab | derivado de quinazolina, composição farmacêutica, uso de um derivado de quinazolina, métodos para produzir um efeito anti - proliferativo em um animal de sangue quente, para prevenção ou tratamento de tumores em um aminal de sangue quente, para fornecer um efeito inibidor da tirosina quinase de egfr seletivo em um animal de sangue quente e para tratar um cáncer em um animal de sangue quente e, processo para a preparação de um derivado de quinazolina |
| GB0322409D0 (en) * | 2003-09-25 | 2003-10-29 | Astrazeneca Ab | Quinazoline derivatives |
| GB0326459D0 (en) | 2003-11-13 | 2003-12-17 | Astrazeneca Ab | Quinazoline derivatives |
| CA2567832A1 (en) * | 2004-06-04 | 2005-12-15 | Astrazeneca Ab | Quinazoline derivatives as erbb receptor tyrosine kinases |
| GB2418427A (en) | 2004-09-02 | 2006-03-29 | Univ Cambridge Tech | Ligands for G-protein coupled receptors |
| ATE501148T1 (de) * | 2004-12-14 | 2011-03-15 | Astrazeneca Ab | Pyrazolopyrimidinverbindungen als antitumormittel |
| GB0504474D0 (en) * | 2005-03-04 | 2005-04-13 | Astrazeneca Ab | Chemical compounds |
| GB0508717D0 (en) * | 2005-04-29 | 2005-06-08 | Astrazeneca Ab | Chemical compounds |
| GB0508715D0 (en) * | 2005-04-29 | 2005-06-08 | Astrazeneca Ab | Chemical compounds |
| WO2007034143A1 (en) * | 2005-09-20 | 2007-03-29 | Astrazeneca Ab | Quinazoline derivatives as anticancer agents |
| ES2354457T3 (es) * | 2005-09-20 | 2011-03-15 | Astrazeneca Ab | Compuestos de 4-(1h-indazol-5-il-amino)-quinazolina como inhibidores del receptor erbb de la tirosina quinasa para el tratamiento del cáncer. |
| JP2009517451A (ja) * | 2005-12-02 | 2009-04-30 | アストラゼネカ アクチボラグ | Erbbチロシンキナーゼの阻害剤として使用されるキナゾリン誘導体 |
| EP1957499A1 (en) * | 2005-12-02 | 2008-08-20 | AstraZeneca AB | 4-anilino-substituted quinazoline derivatives as tyrosine kinase inhibitors |
| EP2144870A2 (en) | 2007-04-27 | 2010-01-20 | Paratek Pharmaceuticals, Inc. | Methods for synthesizing and purifying aminoalkyl tetracycline compounds |
| WO2009009042A1 (en) | 2007-07-06 | 2009-01-15 | Paratek Pharmaceuticals, Inc. | Methods for synthesizing substituted tetracycline compounds |
| US7662967B2 (en) | 2007-08-02 | 2010-02-16 | Cambridge Enterprise Limited | Anti-inflammatory compounds and compositions |
| GB2452696B (en) | 2007-08-02 | 2009-09-23 | Cambridge Entpr Ltd | 3-(2',2'-dimethylpropanoylamino)-tetrahydropyridin-2-one and its use in pharmaceutical compositions |
| GB201604329D0 (en) * | 2016-03-14 | 2016-04-27 | Univ Strathclyde | Methods and systems for improving stability of a ship |
| CN111777620A (zh) * | 2019-04-04 | 2020-10-16 | 山东轩竹医药科技有限公司 | 酪氨酸激酶抑制剂的新用途 |
Family Cites Families (98)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4335127A (en) | 1979-01-08 | 1982-06-15 | Janssen Pharmaceutica, N.V. | Piperidinylalkyl quinazoline compounds, composition and method of use |
| KR910006138B1 (ko) | 1986-09-30 | 1991-08-16 | 에자이 가부시끼가이샤 | 환상아민 유도체 |
| US4921863A (en) | 1988-02-17 | 1990-05-01 | Eisai Co., Ltd. | Cyclic amine derivatives |
| US5721237A (en) | 1991-05-10 | 1998-02-24 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties |
| AU661533B2 (en) | 1992-01-20 | 1995-07-27 | Astrazeneca Ab | Quinazoline derivatives |
| GB9510757D0 (en) | 1994-09-19 | 1995-07-19 | Wellcome Found | Therapeuticaly active compounds |
| ATE446955T1 (de) | 1995-03-30 | 2009-11-15 | Pfizer Prod Inc | Chinazolinone derivate |
| GB9508535D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivative |
| GB9508565D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quiazoline derivative |
| GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
| EP0824525B1 (en) | 1995-04-27 | 2001-06-13 | AstraZeneca AB | Quinazoline derivatives |
| GB9508537D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
| US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
| GB9514265D0 (en) | 1995-07-13 | 1995-09-13 | Wellcome Found | Hetrocyclic compounds |
| CA2242425C (en) | 1996-02-13 | 2006-07-18 | Zeneca Limited | Quinazoline derivatives as vegf inhibitors |
| GB9603095D0 (en) | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
| CN100503580C (zh) | 1996-04-12 | 2009-06-24 | 沃尼尔·朗伯公司 | 酪氨酸激酶的不可逆抑制剂 |
| GB9607729D0 (en) | 1996-04-13 | 1996-06-19 | Zeneca Ltd | Quinazoline derivatives |
| US6391874B1 (en) | 1996-07-13 | 2002-05-21 | Smithkline Beecham Corporation | Fused heterocyclic compounds as protein tyrosine kinase inhibitors |
| GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| EP0837063A1 (en) | 1996-10-17 | 1998-04-22 | Pfizer Inc. | 4-Aminoquinazoline derivatives |
| ZA986732B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitiors of tyrosine kinases |
| GB9800575D0 (en) * | 1998-01-12 | 1998-03-11 | Glaxo Group Ltd | Heterocyclic compounds |
| WO2000009481A1 (en) | 1998-08-11 | 2000-02-24 | Takeda Chemical Industries, Ltd. | Cyclic amide compounds, process for producing the same, intermediates thereof and herbicides |
| HU230728B1 (hu) | 1998-09-29 | 2017-12-28 | Wyeth Holdings Llc | Szubsztituált 3-cianokinolinok mint protein tirozin kinázok inhibitorai |
| US6297258B1 (en) | 1998-09-29 | 2001-10-02 | American Cyanamid Company | Substituted 3-cyanoquinolines |
| CN1158266C (zh) * | 1998-10-01 | 2004-07-21 | 阿斯特拉曾尼卡有限公司 | 化合物 |
| TW575567B (en) | 1998-10-23 | 2004-02-11 | Akzo Nobel Nv | Serine protease inhibitor |
| UA71945C2 (en) | 1999-01-27 | 2005-01-17 | Pfizer Prod Inc | Substituted bicyclic derivatives being used as anticancer agents |
| TR200102505T2 (tr) | 1999-02-27 | 2003-01-21 | Boehringer Ingelheim Pharma Kg | 4-amino-kinazolin ve kinolin türevleri. |
| DE19911509A1 (de) | 1999-03-15 | 2000-09-21 | Boehringer Ingelheim Pharma | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
| US6258820B1 (en) | 1999-03-19 | 2001-07-10 | Parker Hughes Institute | Synthesis and anti-tumor activity of 6,7-dialkoxy-4-phenylamino-quinazolines |
| NZ516633A (en) | 1999-06-21 | 2004-09-24 | Boehringer Ingelheim Pharma | Bicyclic heterocycles, medicaments containing these compounds, their use and methods for the production thereof |
| KR20020029419A (ko) | 1999-07-07 | 2002-04-18 | 다비드 에 질레스 | 퀴나졸린 유도체 |
| GB9917408D0 (en) | 1999-07-23 | 1999-09-22 | Smithkline Beecham Plc | Compounds |
| GB9922171D0 (en) | 1999-09-21 | 1999-11-17 | Zeneca Ltd | Chemical compounds |
| EE200200119A (et) | 1999-09-21 | 2003-04-15 | Astrazeneca Ab | Kinasoliini derivaadid ja nende kasutamine ravimitena |
| PT1244647E (pt) | 1999-11-05 | 2006-10-31 | Astrazeneca Ab | Derivados de quinazolina como inibidores de vegf |
| AU2001235804A1 (en) | 2000-03-06 | 2001-09-17 | Astrazeneca Ab | Therapy |
| UA73993C2 (uk) | 2000-06-06 | 2005-10-17 | Астразенека Аб | Хіназолінові похідні для лікування пухлин та фармацевтична композиція |
| CN1437594A (zh) | 2000-06-22 | 2003-08-20 | 辉瑞产品公司 | 用于治疗异常细胞生长的取代的双环衍生物 |
| WO2002002534A1 (en) | 2000-07-03 | 2002-01-10 | Astrazeneca Ab | Quinazolines with therapeutic use |
| CN1452619A (zh) | 2000-07-26 | 2003-10-29 | 史密斯克莱·比奇曼公司 | 具有抗细菌活性的氨基哌啶喹啉和它们的氮杂等排的类似物 |
| DE10040527A1 (de) | 2000-08-18 | 2002-02-28 | Boehringer Ingelheim Pharma | Chinazoline und Verfahren zu ihrer Herstellung |
| AU2001278609B2 (en) | 2000-08-21 | 2005-04-14 | Astrazeneca Ab | Quinazoline derivatives |
| US20020082270A1 (en) | 2000-08-26 | 2002-06-27 | Frank Himmelsbach | Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases |
| DE10042059A1 (de) | 2000-08-26 | 2002-03-07 | Boehringer Ingelheim Pharma | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
| US6617329B2 (en) | 2000-08-26 | 2003-09-09 | Boehringer Ingelheim Pharma Kg | Aminoquinazolines and their use as medicaments |
| EP1719770A3 (en) | 2000-09-21 | 2008-03-05 | Smithkline Beecham Plc | Quinoline derivatives as antibacterials |
| WO2002030924A1 (en) | 2000-10-13 | 2002-04-18 | Astrazeneca Ab | Quinazoline derivatives with anti-tumour activity |
| US20040063733A1 (en) | 2000-10-25 | 2004-04-01 | Lambert Christine Marie Paul | Quinazoline derivatives |
| US7067532B2 (en) | 2000-11-02 | 2006-06-27 | Astrazeneca | Substituted quinolines as antitumor agents |
| AU2002223684A1 (en) | 2000-11-22 | 2002-06-03 | Novartis Pharma Gmbh | Combination comprising an agent decreasing vegf activity and an agent decreasing egf activity |
| AUPR201600A0 (en) | 2000-12-11 | 2001-01-11 | Fujisawa Pharmaceutical Co., Ltd. | Quinazolinone derivative |
| GB0101577D0 (en) | 2001-01-22 | 2001-03-07 | Smithkline Beecham Plc | Compounds |
| WO2002062767A1 (en) | 2001-02-07 | 2002-08-15 | Sumitomo Pharmaceuticals Company, Limited | Novel quinazoline derivatives |
| NZ516873A (en) | 2001-02-12 | 2003-11-28 | Warner Lambert Co | Compositions containing retinoids and erb inhibitors and their use in inhibiting retinoid skin damage |
| JP4285996B2 (ja) | 2001-02-21 | 2009-06-24 | 田辺三菱製薬株式会社 | キナゾリン誘導体 |
| MXPA03007621A (es) | 2001-02-23 | 2003-12-04 | Merck & Co Inc | Antagonistas nr2b de n-metil-d-aspartato no arilheterociclicos n-sustituidos. |
| US6562319B2 (en) | 2001-03-12 | 2003-05-13 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Radiolabeled irreversible inhibitors of epidermal growth factor receptor tyrosine kinase and their use in radioimaging and radiotherapy |
| HN2002000067A (es) | 2001-03-23 | 2003-10-24 | Bayer Healthcare Llc | Inhibidores de la rho - quinasa. |
| WO2002092578A1 (en) | 2001-05-14 | 2002-11-21 | Astrazeneca Ab | Quinazoline derivatives |
| WO2002092577A1 (en) | 2001-05-14 | 2002-11-21 | Astrazeneca Ab | Quinazoline derivatives |
| US20040176361A1 (en) | 2001-05-23 | 2004-09-09 | Masakazu Fujio | Fused heterocyclic compound and medicinal use thereof |
| CA2349044A1 (en) | 2001-05-28 | 2002-11-28 | Optenia, Inc. | Method of polarisation compensation in grating-and phasar-based devices by using overlayer deposited on the compensating region to modify local slab waveguide birefringence |
| RU2004116911A (ru) | 2001-11-03 | 2005-11-10 | Астразенека Аб (Se) | Производные хиназолина в качестве противоопухолевых средств |
| GB0126433D0 (en) | 2001-11-03 | 2002-01-02 | Astrazeneca Ab | Compounds |
| IL161908A0 (en) | 2001-12-12 | 2005-11-20 | Pfizer Prod Inc | Quinazoline derivatives for the treatment of abnormal cell growth |
| TW200813014A (en) | 2002-03-28 | 2008-03-16 | Astrazeneca Ab | Quinazoline derivatives |
| US6924285B2 (en) | 2002-03-30 | 2005-08-02 | Boehringer Ingelheim Pharma Gmbh & Co. | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them |
| NZ536114A (en) | 2002-03-30 | 2007-11-30 | Boehringer Ingelheim Pharma | 4-(N-phenylamino)-quinazolines / quinolines as tyrosine kinase inhibitors |
| JP2006515871A (ja) | 2003-01-23 | 2006-06-08 | ティー.ケイ. シグナル リミテッド | 上皮増殖因子受容体チロシンキナーゼの不可逆阻害剤ならびにその使用 |
| GB0309009D0 (en) | 2003-04-22 | 2003-05-28 | Astrazeneca Ab | Quinazoline derivatives |
| GB0309850D0 (en) | 2003-04-30 | 2003-06-04 | Astrazeneca Ab | Quinazoline derivatives |
| GB0317665D0 (en) | 2003-07-29 | 2003-09-03 | Astrazeneca Ab | Qinazoline derivatives |
| CA2533345A1 (en) | 2003-07-29 | 2005-02-10 | Astrazeneca Ab | Piperidyl-quinazoline derivatives as tyrosine kinase inhibitors |
| GB0318423D0 (en) | 2003-08-06 | 2003-09-10 | Astrazeneca Ab | Chemical compounds |
| BRPI0414488A (pt) | 2003-09-16 | 2006-11-14 | Astrazeneca Ab | derivado de quinazolina, composição farmacêutica, uso de um derivado de quinazolina, métodos para produzir um efeito anti - proliferativo em um animal de sangue quente, para prevenção ou tratamento de tumores em um aminal de sangue quente, para fornecer um efeito inibidor da tirosina quinase de egfr seletivo em um animal de sangue quente e para tratar um cáncer em um animal de sangue quente e, processo para a preparação de um derivado de quinazolina |
| MXPA06002963A (es) | 2003-09-16 | 2006-06-14 | Astrazeneca Ab | Derivados de quinazolina como inhibidores de cinasa de tirosina. |
| WO2005026156A1 (en) | 2003-09-16 | 2005-03-24 | Astrazeneca Ab | Quinazoline derivatives |
| GB0321648D0 (en) | 2003-09-16 | 2003-10-15 | Astrazeneca Ab | Quinazoline derivatives |
| WO2005026150A1 (en) | 2003-09-16 | 2005-03-24 | Astrazeneca Ab | Quinazoline derivatives as tyrosine kinase inhibitors |
| BRPI0414532B1 (pt) | 2003-09-19 | 2018-06-05 | Astrazeneca Ab | Composto derivado de quinazolina, processo para preparar 0 mesmo, composição farmaceutica, e, uso de um composto derivado de quinazolina |
| DE602004004811T2 (de) | 2003-09-19 | 2007-11-22 | Astrazeneca Ab | Chinazolinderivate |
| GB0322409D0 (en) | 2003-09-25 | 2003-10-29 | Astrazeneca Ab | Quinazoline derivatives |
| MXPA06003341A (es) | 2003-09-25 | 2006-06-08 | Astrazeneca Ab | Derivados de quinazolina. |
| GB0326459D0 (en) | 2003-11-13 | 2003-12-17 | Astrazeneca Ab | Quinazoline derivatives |
| CA2567832A1 (en) | 2004-06-04 | 2005-12-15 | Astrazeneca Ab | Quinazoline derivatives as erbb receptor tyrosine kinases |
| ATE501148T1 (de) | 2004-12-14 | 2011-03-15 | Astrazeneca Ab | Pyrazolopyrimidinverbindungen als antitumormittel |
| AU2006217738A1 (en) | 2005-02-26 | 2006-08-31 | Astrazeneca Ab | Quinazoline derivatives as tyrosine kinase inhibitors |
| GB0504475D0 (en) | 2005-03-04 | 2005-04-13 | Astrazeneca Ab | Chemical compounds |
| GB0504474D0 (en) | 2005-03-04 | 2005-04-13 | Astrazeneca Ab | Chemical compounds |
| GB0508717D0 (en) | 2005-04-29 | 2005-06-08 | Astrazeneca Ab | Chemical compounds |
| GB0508715D0 (en) | 2005-04-29 | 2005-06-08 | Astrazeneca Ab | Chemical compounds |
| WO2007034143A1 (en) | 2005-09-20 | 2007-03-29 | Astrazeneca Ab | Quinazoline derivatives as anticancer agents |
| ES2354457T3 (es) | 2005-09-20 | 2011-03-15 | Astrazeneca Ab | Compuestos de 4-(1h-indazol-5-il-amino)-quinazolina como inhibidores del receptor erbb de la tirosina quinasa para el tratamiento del cáncer. |
| EP1957499A1 (en) | 2005-12-02 | 2008-08-20 | AstraZeneca AB | 4-anilino-substituted quinazoline derivatives as tyrosine kinase inhibitors |
| JP2009517451A (ja) | 2005-12-02 | 2009-04-30 | アストラゼネカ アクチボラグ | Erbbチロシンキナーゼの阻害剤として使用されるキナゾリン誘導体 |
-
2005
- 2005-01-31 AT AT05701999T patent/ATE413389T1/de not_active IP Right Cessation
- 2005-01-31 EP EP05701999A patent/EP1713781B1/en not_active Expired - Lifetime
- 2005-01-31 WO PCT/GB2005/000237 patent/WO2005075439A1/en not_active Ceased
- 2005-01-31 US US10/586,965 patent/US7632840B2/en not_active Expired - Fee Related
- 2005-01-31 JP JP2006551898A patent/JP5032851B2/ja not_active Expired - Fee Related
- 2005-01-31 DE DE602005010824T patent/DE602005010824D1/de not_active Expired - Lifetime
- 2005-01-31 CN CN2005800038578A patent/CN1914182B/zh not_active Expired - Fee Related
- 2005-01-31 ES ES05701999T patent/ES2315834T3/es not_active Expired - Lifetime
- 2005-02-02 UY UY28736A patent/UY28736A1/es unknown
- 2005-02-03 TW TW094103412A patent/TW200529851A/zh unknown
- 2005-02-03 AR ARP050100415A patent/AR047703A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AR047703A1 (es) | 2006-02-08 |
| WO2005075439A1 (en) | 2005-08-18 |
| EP1713781A1 (en) | 2006-10-25 |
| CN1914182A (zh) | 2007-02-14 |
| US7632840B2 (en) | 2009-12-15 |
| ES2315834T3 (es) | 2009-04-01 |
| CN1914182B (zh) | 2011-09-07 |
| TW200529851A (en) | 2005-09-16 |
| UY28736A1 (es) | 2005-09-30 |
| JP2007523072A (ja) | 2007-08-16 |
| US20070293490A1 (en) | 2007-12-20 |
| EP1713781B1 (en) | 2008-11-05 |
| HK1095590A1 (en) | 2007-05-11 |
| DE602005010824D1 (de) | 2008-12-18 |
| ATE413389T1 (de) | 2008-11-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1713781B1 (en) | Quinazoline derivatives | |
| US7569577B2 (en) | Quinazoline derivatives as tyrosine kinase inhibitors | |
| JP3891493B2 (ja) | 抗腫瘍剤としての4−アニリノキナゾリン誘導体 | |
| US7838530B2 (en) | Quinazoline derivatives as antiproliferative agents | |
| EP1667996B1 (en) | Quinazoline derivatives | |
| US20070032508A1 (en) | Quinazoline derivatives as tyrosine kinase inhibitors | |
| JP2007505874A (ja) | 抗腫瘍剤としてのキナゾリン誘導体 | |
| US20080234263A1 (en) | Quinazoline Derivatives | |
| KR20070038500A (ko) | erbB 수용체 타이로신 키나제로서의 퀴나졸린 유도체 | |
| KR20060127410A (ko) | 퀴나졸린 유도체 | |
| KR101244524B1 (ko) | 티로신 키나제 억제제로서의 퀴나졸린 유도체 | |
| HK1095590B (en) | Quinazoline derivatives | |
| KR20070023630A (ko) | 티로신 키나제 억제제로서의 퀴나졸린 유도체 | |
| KR20070017969A (ko) | 퀴나졸린 유도체 | |
| HK1091479B (en) | Quinazoline derivatives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080130 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20080130 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20101201 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20101208 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20110225 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20110304 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110531 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20110905 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20111201 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20120221 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120228 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120516 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20120607 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20120629 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20150706 Year of fee payment: 3 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |